Literature DB >> 16690611

Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor.

Shin-ichiro Miura1, Masahiro Fujino, Hiroyuki Hanzawa, Yoshihiro Kiya, Satoshi Imaizumi, Yoshino Matsuo, Sayo Tomita, Yoshinari Uehara, Sadashiva S Karnik, Hiroaki Yanagisawa, Hiroyuki Koike, Issei Komuro, Keijiro Saku.   

Abstract

To delineate the molecular mechanism underlying the inverse agonist activity of olmesartan, a potent angiotensin II type 1 (AT1) receptor antagonist, we performed binding affinity studies and an inositol phosphate production assay. Binding affinity of olmesartan and its related compounds to wild-type and mutant AT1 receptors demonstrated that interactions between olmesartan and Tyr113, Lys199, His256, and Gln257 in the AT1 receptor were important. The inositol phosphate production assay of olmesartan and related compounds using mutant receptors indicated that the inverse agonist activity required two interactions, that between the hydroxyl group of olmesartan and Tyr113 in the receptor and that between the carboxyl group of olmesartan and Lys199 and His256 in the receptor. Gln257 was found to be important for the interaction with olmesartan but not for the inverse agonist activity. Based on these results, we constructed a model for the interaction between olmesartan and the AT1 receptor. Although the activation of G protein-coupled receptors is initiated by anti-clockwise rotation of transmembrane (TM) III and TM VI followed by changes in the conformation of the receptor, in this model, cooperative interactions between the hydroxyl group and Tyr113 in TM III and between the carboxyl group and His256 in TM VI were essential for the potent inverse agonist activity of olmesartan. We speculate that the specific interaction of olmesartan with these two TMs is essential for stabilizing the AT1 receptor in an inactive conformation. A better understanding of the molecular mechanisms of the inverse agonism could be useful for the development of new G protein-coupled receptor antagonists with inverse agonist activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690611     DOI: 10.1074/jbc.M602144200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Functional intracellular renin-angiotensin systems: potential for pathophysiology of disease.

Authors:  Robert M Carey
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.

Authors:  Toshihide Kawai; Izumi Takei; Akira Shimada; Takumi Hirata; Kumiko Tanaka; Yoshifumi Saisho; Junichiro Irie; Chihiro Horimai; Hideo Matsumoto; Hiroshi Itoh
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation.

Authors:  Noritaka Yasuda; Shin-ichiro Miura; Hiroshi Akazawa; Toshimasa Tanaka; Yingjie Qin; Yoshihiro Kiya; Satoshi Imaizumi; Masahiro Fujino; Kaoru Ito; Yunzeng Zou; Shigetomo Fukuhara; Satoshi Kunimoto; Koichi Fukuzaki; Toshiaki Sato; Junbo Ge; Naoki Mochizuki; Haruaki Nakaya; Keijiro Saku; Issei Komuro
Journal:  EMBO Rep       Date:  2008-01-18       Impact factor: 8.807

5.  Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.

Authors:  Mark A Munger
Journal:  P T       Date:  2011-01

6.  Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out.

Authors:  Yoshihiro Kiya; Shin-ichiro Miura; Yoshino Matsuo; Sadashiva S Karnik; Keijiro Saku
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-08-08       Impact factor: 1.636

7.  Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.

Authors:  Shin-ichiro Miura; Atsutoshi Okabe; Yoshino Matsuo; Sadashiva S Karnik; Keijiro Saku
Journal:  Hypertens Res       Date:  2012-10-04       Impact factor: 3.872

8.  Do all angiotensin II type 1 receptor blockers have the same beneficial effects?

Authors:  S Miura; K Saku
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

9.  Rab1 GTPase and dimerization in the cell surface expression of angiotensin II type 2 receptor.

Authors:  Xiaoping Zhang; Guansong Wang; Denis J Dupré; Yumei Feng; Mélanie Robitaille; Eric Lazartigues; Ying-Hong Feng; Terence E Hébert; Guangyu Wu
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

10.  Effects of angiotensin II AT₁-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats.

Authors:  Shinji Kosaka; Nicolas Pelisch; Matlubur Rahman; Daisuke Nakano; Hirofumi Hitomi; Hiroyuki Kobori; Noriyasu Fukuoka; Hideki Kobara; Hirohito Mori; Tsutomu Masaki; Ludek Cervenka; Yasuo Matsumura; Hitoshi Houchi; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2013-01-22       Impact factor: 3.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.